Online citations, reference lists, and bibliographies.
← Back to Search

Cell-Mediated Release Of Nanoparticles As A Preferential Option For Future Treatment Of Melanoma

A. Chillà, F. Margheri, A. Biagioni, T. Del Rosso, G. Fibbi, M. Del Rosso, Anna Laurenzana
Published 2020 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Targeted and immune therapies have unquestionably improved the prognosis of melanoma patients. However the treatment of this neoplasm still requires approaches with a higher therapeutic index, in order to reduce shortcomings related to toxic effects and aspecific targeting. This means developing therapeutic tools derived with high affinity molecules for tumor components differentially expressed in melanoma cells with respect to their normal counterpart. Nanomedicine has sought to address this problem owing to the high modulability of nanoparticles. This approach exploits not only the enhanced permeability and retention effect typical of the tumor microenvironment (passive targeting), but also the use of specific “molecular antennas” that recognize some tumor-overexpressed molecules (active targeting). This line of research has given rise to the so-called “smart nanoparticles,” some of which have already passed the preclinical phase and are under clinical trials in melanoma patients. To further improve nanoparticles partition within tumors, for some years now a line of thought is exploiting the molecular systems that regulate the innate tumor-homing activity of platelets, granulocytes, monocytes/macrophages, stem cells, endothelial-colony-forming cells, and red blood cells loaded with nanoparticles. This new vision springs from the results obtained with some of these cells in regenerative medicine, an approach called “cell therapy.” This review takes into consideration the advantages of cell therapy as the only one capable of overcoming the limits of targeting imposed by the increased interstitial pressure of tumors.
This paper references
10.1021/acsnano.7b08355
Erythrocyte-Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma.
D. Wang (2018)
10.1038/nrc.2016.52
Neutrophils in cancer: neutral no more
S. Coffelt (2016)
10.1152/PHYSREV.1990.70.4.987
Microlymphatics and lymph flow.
G. W. Schmid-Schönbein (1990)
10.1002/adhm.201500998
Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy.
Dafeng Chu (2016)
10.1186/s40169-018-0185-6
Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs
H. Maeda (2018)
10.1158/1078-0432.CCR-05-0343
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Kimberley M Laginha (2005)
10.1021/BC700184B
A macrophage-nanozyme delivery system for Parkinson's disease.
E. Batrakova (2007)
10.1055/S-2004-822974
Platelets and angiogenesis in malignancy.
E. Sierko (2004)
10.1084/jem.20090687
Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo
S. Momi (2009)
10.1182/blood-2011-02-338681
Endothelial progenitor cell-dependent angiogenesis requires localization of the full-length form of uPAR in caveolae.
F. Margheri (2011)
10.1158/0008-5472.CAN-09-1912
Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles.
M. Loebinger (2009)
10.1038/nrc3004
Contribution of platelets to tumour metastasis
Laurie J. Gay (2011)
10.2147/ITT.S134842
Melanoma treatment in review
B. Domingues (2018)
10.1016/j.xphs.2017.06.019
Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
Az Alddien Natfji (2017)
10.1182/BLOOD-2006-08-043471
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.
M. Yoder (2007)
10.1073/pnas.1006375107
Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis
K. Carbajal (2010)
10.1038/ncomms10593
Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma
J. Bagó (2016)
10.1038/sj.leu.2404676
Working hypothesis to redefine endothelial progenitor cells
D. Prater (2007)
10.1016/j.biomaterials.2016.11.048
Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.
R. Jones (2017)
10.3389/fimmu.2018.00262
How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive
A. Poggi (2018)
10.1093/bmb/ldy029
The role of neutrophils in cancer
R. Grecian (2018)
10.1038/s41551-017-0139-0
Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity
N. Tanaka (2017)
10.7150/thno.36510
Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery
D. Sun (2019)
10.2147/IJN.S28344
Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model
Matthew T. Basel (2012)
Prognostic value of neutrophil-to-lymphocyte ratio in melanoma. Evidence from a PRISMA-compliant meta-analysis. Medicine (Baltimore
Y. Ding (2018)
Intracellular dis-tribution of macrophage migration inhibitory factor predicts the prognosis ofpatients with adenocarcinoma of the lung. Cancer
A Kamimura (2000)
10.1016/j.ymeth.2015.08.013
Neural stem cell therapy for cancer.
J. Bagó (2016)
10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N
Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung
A. Kamimura (2000)
10.3181/00379727-232-2320958
Long Circulating Nanoparticles via Adhesion on Red Blood Cells: Mechanism and Extended Circulation
E. Chambers (2007)
10.1016/j.thromres.2016.01.009
NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation.
C. Thålin (2016)
10.3390/cancers11040564
Tumor-Associated Neutrophils in Cancer: Going Pro
L. Wu (2019)
10.15283/ijsc17028
A Simple Method to Isolate and Expand Human Umbilical Cord Derived Mesenchymal Stem Cells: Using Explant Method and Umbilical Cord Blood Serum
G. Hassan (2017)
10.1002/ijc.31792
Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes
Ursula Altanerova (2019)
Induction of pluripotent stem
K. Takahashi
10.1016/J.JCONREL.2004.08.005
Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes.
E. Chambers (2004)
10.1097/00001721-200101000-00007
Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor
A. Blann (2001)
10.1016/j.neuron.2013.10.037
Neural Stem Cells: Generating and Regenerating the Brain
F. Gage (2013)
10.1021/acsnano.5b01042
Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Y. Guo (2015)
Prognostic value of neutrophil - to - lymphocyte ratio in melanoma . Evidence from a PRISMA - compliant meta - analysis
Y. Ding (2018)
10.1002/cncr.10354
Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma
K. Meyer-Siegler (2002)
10.1016/j.biomaterials.2012.11.032
Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery.
Xinglu Huang (2013)
10.1016/S1074-7613(03)00263-2
Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence.
C. Martin (2003)
10.4049/jimmunol.1402097
Macrophage Migration Inhibitory Factor–CXCR4 Is the Dominant Chemotactic Axis in Human Mesenchymal Stem Cell Recruitment to Tumors
S. Lourenco (2015)
10.1038/bmt.2008.76
Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health
N. Sacchi (2008)
10.1016/j.addr.2018.07.007
Tumor targeting via EPR: Strategies to enhance patient responses.
Susanne K Golombek (2018)
Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.
H. M. Verheul (2000)
10.1002/btm2.10143
Nanoparticles in the clinic: An update
Aaron C. Anselmo (2019)
10.3389/fmed.2018.00354
Recent Advances in Endothelial Progenitor Cells Toward Their Use in Clinical Translation
C. Keighron (2018)
10.1002/sctm.16-0360
Endothelial Progenitors: A Consensus Statement on Nomenclature
Reinhold J Medina (2017)
10.1016/j.jcyt.2013.01.215
Recruitment of human cord blood-derived endothelial colony-forming cells to sites of tumor angiogenesis.
K. Bieback (2013)
10.1016/j.it.2016.03.009
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis.
M. Hölzel (2016)
10.1182/blood.v63.1.55.55
Potential role of platelets in the pathogenesis of tumor metastasis.
P. Mehta (1984)
10.2217/IIM.12.35
Cord blood endothelial progenitor cells as therapeutic and imaging probes.
B. Janic (2012)
10.1016/j.jconrel.2014.03.050
Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.
Aaron C. Anselmo (2014)
10.1038/sj.bjp.0706013
Platelet–cancer interactions: mechanisms and pharmacology of tumour cell‐induced platelet aggregation
P. Jurasz (2004)
10.1038/s41389-017-0011-9
The hypoxic tumour microenvironment
V. Petrova (2018)
Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance.
M. Tomiyasu (2002)
10.1038/s41598-017-15081-6
Protein profiling identified key chemokines that regulate the maintenance of human pluripotent stem cells
Zongmin Jiang (2017)
10.3322/caac.21208
Cancer statistics, 2014
R. Siegel (2014)
10.1182/blood-2008-09-176198
Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells.
Keishi Otsu (2009)
10.1186/1755-8794-3-18
Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities
R. Medina (2009)
10.2217/nnm.15.111
Nanoparticle-mediated drug delivery for treating melanoma.
Vaibhav Mundra (2015)
10.1182/blood.v96.5.1789
Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions.
O. McCarty (2000)
Pathophisiology of Edema Formation. Capillary Fluid Exchange: Regulation, Functions, and Pathology; Morgan&Claypool Life Sciences
J. Scallan (2010)
10.1155/2012/948098
Macrophages in Tumor Microenvironments and the Progression of Tumors
Ningbo Hao (2012)
10.1038/nm.3909
The prognostic landscape of genes and infiltrating immune cells across human cancers
A. Gentles (2015)
10.1023/A:1018907715905
Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs
A. Gabizon (2004)
10.1038/s41598-019-57240-x
Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy
K. J. Mahasa (2020)
10.1021/ACSAMI.6B10175
Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy.
Yanna Cui (2016)
10.2147/IJN.S152461
Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs)
M. Shevtsov (2018)
10.1242/jcs.116392
The tumor microenvironment at a glance
F. Balkwill (2012)
10.1053/J.SEMINONCOL.2005.11.011
Renal toxicities of chemotherapy.
M. D. de Jonge (2006)
10.1080/2162402X.2015.1134073
Priming of neutrophils toward NETosis promotes tumor growth
Mélanie Demers (2016)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1016/j.chembiol.2018.03.003
Cellular Cyborgs: On the Precipice of a Drug Delivery Revolution.
S. Ding (2018)
10.1200/JCO.2016.66.7220
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.
S. Goff (2016)
10.1080/15384047.2019.1640032
Current state of melanoma diagnosis and treatment
L. Davis (2019)
10.1038/427695A
Pathology: Cancer cells compress intratumour vessels
T. Padera (2004)
10.1016/S0002-9440(10)65006-7
Openings between defective endothelial cells explain tumor vessel leakiness.
H. Hashizume (2000)
10.1002/JLB.3MR0717-292R
Roles of neutrophils in cancer growth and progression
M. R. Galdiero (2018)
10.18632/oncotarget.9511
Tumor-tropic endothelial colony forming cells (ECFCs) loaded with near-infrared sensitive Au nanoparticles: A “cellular stove” approach to the photoablation of melanoma
G. Margheri (2016)
10.1083/JCB.27.3.531
PLATELET PHAGOCYTOSIS AND AGGREGATION
H. Movat (1965)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
10.1371/journal.pone.0172788
Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis
Katrin Echtler (2017)
10.3389/fbioe.2020.00133
Platelet-Like Gold Nanostars for Cancer Therapy: The Ability to Treat Cancer and Evade Immune Reactions
Min Woo Kim (2020)
10.1073/pnas.1700363114
Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas
Wanlu Du (2017)
10.1182/blood-2009-10-247296
Deadly allies: the fatal interplay between platelets and metastasizing cancer cells.
Luise Erpenbeck (2010)
10.1111/j.1349-7006.2005.00032.x
Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy
H. Hamada (2005)
10.2174/0929867323666151217122033
Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents.
H. Mirzaei (2016)
10.1016/j.jconrel.2016.11.015
To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
F. Danhier (2016)
10.1083/jcb.201102147
The extracellular matrix: A dynamic niche in cancer progression
Pengfei Lu (2012)
10.1002/adma.201004074
Cell-based drug delivery devices using phagocytosis-resistant backpacks.
N. Doshi (2011)
10.1021/nn100870z
Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells.
R. S. Rachakatla (2010)
10.1166/JNN.2012.6644
Differential immunomodulating effects of pegylated liposomal doxorubicin nanoparticles on human macrophages.
Chia-Yuan Liu (2012)
10.1021/NL072209H
A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors.
M. Choi (2007)
10.1002/ijc.31937
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay (2019)
10.1007/s00432-018-2726-1
Melanoma treatment: from conventional to nanotechnology
Harshita Mishra (2018)
10.1155/2018/3057624
Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application
M. Wang (2018)
10.1155/2019/3702518
Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine
D. Lombardo (2019)
10.1517/17425247.2015.966684
Leukocytes as carriers for targeted cancer drug delivery
Michael J Mitchell (2015)
10.1016/S1470-2045(13)70333-4
The scope of nanoparticle therapies for future metastatic melanoma treatment.
F. B. Bombelli (2014)
10.1038/s41419-018-0876-3
CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling
N. Wang (2018)
10.1007/978-1-59745-060-7_18
Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium.
M. Gnecchi (2009)
10.1084/JEM.20151665
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
T. Chan (2016)
10.1016/j.jid.2018.07.006
CXCL5 as Regulator of Neutrophil Function in Cutaneous Melanoma.
A. Forsthuber (2019)
10.1200/JCO.2005.00.240
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
M. Dudley (2005)
10.1038/ncomms9692
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
Miles A. Miller (2015)
10.3892/or.2017.5718
Cancer drug delivery in the nano era: An overview and perspectives
Z. Li (2017)
10.1017/S1462399401003301
Chemokines in cancer.
M. Frederick (2001)
10.1016/0952-3278(95)90085-3
Platelet activation and platelet lipid composition in pulmonary cancer.
D. Prisco (1995)
10.1016/0277-5379(89)90098-9
Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma).
P. Mannucci (1989)
10.1089/hum.2016.066
Endothelial Progenitor Cells as Shuttle of Anticancer Agents.
A. Laurenzana (2016)
10.1021/acsnano.5b02207
Mesenchymal Stem Cells Aggregate and Deliver Gold Nanoparticles to Tumors for Photothermal Therapy.
S. Kang (2015)
10.1172/JCI15849
Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury.
J. Belperio (2002)
10.1016/j.cell.2006.07.024
Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors
Kazutoshi Takahashi (2006)
10.1016/j.jid.2018.01.035
CXCL5 Facilitates Melanoma Cell-Neutrophil Interaction and Lymph Node Metastasis.
A. Soler-Cardona (2018)
10.1007/s11033-011-0720-7
A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma
Gwi-Moon Seo (2011)
10.1080/09537104.2019.1572879
Platelet count correlates with stage and predicts survival in melanoma
S. Rachidi (2019)
10.1158/0008-5472.CAN-13-3696
Releasing pressure in tumors: what do we know so far and where do we go from here? A review.
A. N. Ariffin (2014)
10.1055/S-2007-1002578
Platelets and cancer metastasis: more than an epiphenomenon.
K. Honn (1992)
10.4199/c00006ed1v01y201002isp003
Capillary Fluid Exchange: Regulation, Functions, and Pathology
Joshua P. Scallan (2010)
10.1172/JCI41649
CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow.
K. J. Eash (2010)
10.1111/j.1365-2567.2008.02950.x
Neutrophil mobilization and clearance in the bone marrow
R. C. Furze (2008)
10.1016/j.ctrv.2018.06.003
It is finally time for adjuvant therapy in melanoma.
S. Napolitano (2018)
10.1182/BLOOD-2004-04-1396
Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood.
D. Ingram (2004)
10.1038/cr.2008.40
Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model
L. Qiao (2008)
10.1021/mp800030k
Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model
Lilian E van Vlerken (2008)
10.1158/2326-6066.CIR-17-0502
CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction
Natnaree Siriwon (2018)
10.1021/nn404853z
Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells.
Aaron C. Anselmo (2013)
10.1038/NATREVMATS.2016.14
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm (2016)
10.1164/RCCM.200301-071OC
The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.
R. J. Phillips (2003)
Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure.
R. Jain (1988)
10.1182/blood-2015-01-624023
P-selectin promotes neutrophil extracellular trap formation in mice.
J. Etulain (2015)
Amelio, I. The hypoxic tumour microenvironment
V Petrova (2018)
10.1080/21691401.2018.1430585
Using gold nanoparticles in diagnosis and treatment of melanoma cancer
S. Bagheri (2018)
10.4172/2157-7439.S4-003
Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease.
Y. Zhao (2011)
10.1158/1535-7163.MCT-12-0529
Targeting CXCR2 Enhances Chemotherapeutic Response, Inhibits Mammary Tumor Growth, Angiogenesis, and Lung Metastasis
B. Sharma (2013)
10.1016/j.mvr.2009.12.004
Endothelial progenitor cells--an evolving story.
J. Pearson (2010)
10.1038/s41598-017-03212-y
Increased platelet distribution width predicts poor prognosis in melanoma patients
N. Li (2017)
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.
K. Harrington (2001)
10.1038/NATREVMATS.2016.69
Cancer nanomedicine: Is targeting our target?
T. Lammers (2016)
10.4110/in.2017.17.5.298
Current Understanding in Neutrophil Differentiation and Heterogeneity
Chang-Won Hong (2017)
Cancer cells compress intratumor vessels: Pressure from proliferating cells impedes transport of therapeutic drugs into tumors
T. P. Padera (2004)
10.1007/s11999-008-0333-1
Expression of Macrophage Migration Inhibitory Factor Relates to Survival in High-grade Osteosarcoma
I. Han (2008)
10.18632/ONCOTARGET.1987
Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme
A. Laurenzana (2014)
10.1002/stem.23
Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell‐Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell‐Conditioned Medium
H. Gao (2009)
10.1093/carcin/bgs123
Tumor-associated neutrophils: friend or foe?
Z. Fridlender (2012)
10.1038/srep42632
Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma
P. Xu (2017)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar